SCHEMBL6897295

SCHEMBL6897295

COC(=O)c1cccc2c1c1c(O)cc(C)cc1n2Cc1ccccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
TP53 P04637 1/20 0.48
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 2/20 0.43
GAA P10253 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TNF P01375 2/20 0.42
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TDP1 Q9NUW8 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6892544 0.89 MAPT (0.44) MAPTTP53ALDH1A1MEN1KMT2A
SCHEMBL6688455 0.89 MAPT (0.48) MAPTTP53ALDH1A1MEN1KMT2A
SCHEMBL6890571 0.89 MAPT (0.45) MAPTTP53ALDH1A1MEN1KMT2A
SCHEMBL6894916 0.89 MAPT (0.45) MAPTTP53ALDH1A1MEN1KMT2A
SCHEMBL6776472 0.88 PLA2G2A (0.44) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL6689196 0.88 GAA (0.47) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL6898392 0.88 L3MBTL1 (0.44) MAPTALDH1A1MEN1KMT2ALMNA
SCHEMBL6894986 0.88 HSP90AA1 (0.38) MAPTTP53ALDH1A1MEN1KMT2A
SCHEMBL6887085 0.87 MAPT (0.44) MAPTTP53ALDH1A1MEN1KMT2A
SCHEMBL6887896 0.87 MAPT (0.44) MAPTTP53ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed